The litigation concerns shares purchased between December 17, 2025, and July 26, 2026. According to the court filing, Capricor failed to secure FDA approval for modifications to the statistical analysis plan used to evaluate clinical data for Deramiocel. Plaintiffs allege that the company’s failure to disclose this lack of consensus rendered its public statements materially misleading, resulting in financial harm to investors.

Shareholders seeking to participate in the litigation or discuss potential lead plaintiff appointments must act before the September 28, 2026 deadline. Participation does not require an appointment as a lead plaintiff to recover losses. The legal action asserts violations of the Securities Exchange Act of 1934, specifically targeting the accuracy of disclosures provided to the market during the specified period.